Dhruv Kotecha*

Department of Clinical Case Report, India

*Corresponding Author: Dhruv Kotecha, Department of Clinical Case Report, India.

Received: January 03, 2025; Published: March 18, 2025

Abstract

Thrombocytopenia is a common clinical condition caused by drugs specifically heparin induced. However to overcome this novel oral anticoagulants have been introduced to overcome this side effect. However still in 1% of cases novel oral anticoagulants too can cause thrombocytopenia. Here we present one such case where thrombocytopenia was caused by APIXABAN and reverted back by Fondaparinaux.

Keywords: Thrombocytopenia; Platelets; Blood

References

1. Philip Young-Ill Choi., et al. “Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology”. Journal of Thrombosis and Haemostasis6 (2024): 1772-1778.
2. Daniel C Dees. “Heparin Induced Thrombocytopenia Testing”. Clinics in Laboratory Medicine3 (2024): 541-550.
3. Hogan M and Berger JS. “Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management”. Vascular Medicine2 (2020): 160-173.
4. Skelly JW., et al. “Novel oral anticoagulants for heparin‐induced thrombocytopenia”. Journal of Thrombosis and Haemostasis 2 (2016): 172‐178.
5. Snellgrove O. “Case report: apixaban‐induced thrombocytopenia”. Clinical Case Report3 (2017): 268‐269.
6. A Greinacher., et al. “Autoimmune heparin-induced thrombocytopenia”. Journal of Thrombosis and Haemostasis11 (2017): 2099-2114.

Citation

Citation: Dhruv Kotecha. “Apixaban Induced Thrombocytopenia: A Rare Event". Acta Scientific Clinical Case Reports 6.4 (2025): 06-07.

Copyright

Copyright: © 2025 Dhruv Kotecha. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.